Claims for Patent: 9,765,137

Summary for Patent: 9,765,137

Title:	Early marker of proteinuria in patients treated with an anti-VEGF treatment
Abstract:	This document provides methods and materials related to determining whether or not a human receiving a therapy (e.g., an anti-VEGF therapy such as a bevacizumab therapy) has developed or is at risk for developing proteinuria. For example, methods and materials for detecting urinary podocytes to determine whether or not a human receiving anti-VEGF therapy has or is at risk for developing proteinuria or kidney injury are provided.
Inventor(s):	Garovic; Vesna D. (Rochester, MN)
Assignee:	Mayo Foundation for Medical Education and Research (Rochester, MN)
Application Number:	14/935,784
Patent Claims:	1. A method for treating a human having cancer in a manner that reduces the likelihood of inducing proteinuria, wherein said method comprises: (a) administering an initial dose of an anti-VEGF therapy to said human to treat said cancer, and (b) administering a subsequent dose of said anti-VEGF therapy to said human, wherein said human, following administration of said initial dose, was identified as having a urine sample that contains podocytes or polypeptides expressed by podocytes, wherein said subsequent dose is at least 30 percent lower than said initial dose. 2. The method of claim 1, wherein said anti-VEGF therapy is selected from the group consisting of a bevacizumab therapy, a sunitinib therapy, and a sorafenib therapy. 3. The method of claim 1, wherein said human is a non-pregnant human. 4. The method of claim 1, wherein said administering said initial dose comprises administering between 5 and 15 mg of said anti-VEGF therapy per kg of body weight of said human per day once every week, once every two weeks, or once every three weeks. 5. The method of claim 1, wherein said urine sample was obtained from said human within at least three days of administration of said initial dose.

Details for Patent 9,765,137

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2029-12-21